How can patients verify whether stem cell clinics offering ED procedures are legitimate? Most of the answer sits in free public records, and the work takes about an evening. This guide covers five checks you can run before paying: the FDA warning letters database, the FDA list of approved cellular and gene therapy products, the FDA consumer alert, the status field on ClinicalTrials.gov, and the written notice your state law may require.
TLDR: Verification is a sequence, not a feeling. Search the clinic, the manufacturer, and the product in the FDA warning letters database. Check the FDA list of approved cellular and gene therapy products, where no stem cell product for erectile dysfunction appears, and read the FDA consumer alert. Look up every cited trial and read the status field, since Unknown, Terminated, and Withdrawn records get quoted as if they were active. Then confirm you received the notice your state requires. Banking adipose tissue does not make any therapy FDA approved and does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a connector service linking patients and providers to a U.S. tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. Adipose tissue and stromal vascular fraction are investigational and not FDA approved, and no stem cell product is approved for erectile dysfunction. This article describes public records and is not legal advice. It is for educational purposes only, and readers should consult their own licensed healthcare professionals before acting on it.
Marketing for erectile dysfunction cell therapy is built to look verified. A site lists an FDA registration number, an accreditation certificate, a trial identifier, and a physician’s photograph. Each element is real in some sense, and none means what the layout suggests.
One caution before you start. Nothing below tells you whether adipose-derived cells help anyone with erectile dysfunction. No product is approved for it. These steps show only whether a clinic describes its regulatory position accurately.
How Can Patients Verify Whether Stem Cell ED Clinics Are Legitimate
Get four things in writing, by email, before you search anything: the exact product name, the manufacturer or tissue bank supplying it, the processing facility, and any trial identifier the clinic cites. A clinic that will not email those has told you something already.
Treat this as an ED clinic FDA compliance check you run yourself. Verifying regenerative medicine clinic legitimacy follows the sequence patients use to verify a banking company: get the names, then look them up.
Step One: Search the FDA Warning Letters Database
The FDA warning letters database is searchable by company name, subject, and issuing office. Search four terms: the clinic’s legal name, any name it does business under, the manufacturer, and the product. Read the letter itself, not a summary.
Three verified letters show what the agency writes. On February 11, 2026 the FDA told Dynamic Stem Cell Therapy of Henderson, Nevada that its umbilical cord derived product was an unapproved new drug and unlicensed biological product, citing more than minimal manipulation, non-homologous use for cardiovascular disease and arthritis, and misbranding. It also flagged exosome marketing. On August 15, 2025 the agency cited Innate Healthcare Institute of Scottsdale, Arizona over an umbilical cord mesenchymal stromal cell product, minimal manipulation failure, non-homologous use including intended treatment of autism, and no biologics license application. On May 5, 2025 it described exosome products from Supreme Rejuvenation LLC of Houston, Texas as unapproved new drugs and unlicensed biologics.
Those phrases mean the agency treated a product as needing approval or a license it did not have. No result means no letter has issued, which is not clearance. Our guide to fake clinic red flags covers what these letters share.
Step Two: Check the FDA List of Approved Cellular and Gene Therapy Products
The FDA publishes one list of approved cellular and gene therapy products. It is short, and for nearly every product a clinic markets, the honest result is that the product is not there. That is the expected answer, not a failed search.
One entry matters because clinics cite it. Ryoncil, approved December 18, 2024, is the first FDA-approved mesenchymal stromal cell therapy. It is allogeneic and bone marrow derived, indicated for steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older, unchanged as of the list current through July 1, 2026. So the only approved therapy of its kind comes from bone marrow, not adipose tissue. Watch also for FDA registered, which means a facility filed paperwork rather than earned approval.
Step Three: Read the FDA Consumer Alert on Regenerative Medicine Products
The FDA’s consumer alert on regenerative medicine products was published July 22, 2020, with content current as of April 9, 2024. It names the conditions these products are marketed for without approval: arthritis, back pain, Parkinson’s disease, ALS, Alzheimer’s disease, cardiovascular and lung disease, autism, blindness, and COVID-19.
Erectile dysfunction is not on that list, and the absence misleads readers. Two statements in the alert apply to every marketed condition: blood-forming stem cells from cord blood are the only approved stem cell products, and no exosome product is FDA approved. That settles the status of any exosome offer.
Step Four: Look Up Every Cited Trial and Read the Status Field
Trial identifiers look like evidence, so clinics print them. Search the identifier on ClinicalTrials.gov and read recruitment status first. The ClinicalTrials.gov glossary defines each status, and three get presented as though they meant activity.
Unknown applies to a study whose last known status was recruiting, not yet recruiting, or active and not recruiting, that passed its completion date without verification in the past two years. Terminated means the study stopped early and will not start again. Withdrawn means it stopped before enrolling its first participant.
Two records make this concrete. NCT06002841, a study of mesenchymal cell derived extracellular vesicles in acute respiratory failure, is Unknown, with a last known status of Not yet recruiting and last verification in August 2023. NCT04371393, a Phase 3 mesenchymal stromal cell trial in COVID-19 acute respiratory distress syndrome, is Terminated because randomization was halted at the third interim analysis for low predictive probability of achieving the postulated mortality benefit. Under 42 CFR Part 11, sponsors must state why a study stopped, so the reason sits in the record.
Step Five: Confirm the Written Notice Your State Requires
Several states require a patient-facing disclosure and a statutory consent, and four fix the exact wording. In Florida, Georgia, Tennessee, or Utah you are entitled to a specific written notice, and its absence is itself a finding.
Florida’s notice, created by CS/CS/SB 1768 and effective July 1, 2025, reads: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
Georgia’s, effective July 1, 2026, reads: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER GEORGIA LAW. This physician or his or her designee performs one or more human stem cell therapies that have not yet been approved by the FDA. You are encouraged to consult with your primary care provider before undergoing any human stem cell therapy.”
Tennessee’s, also effective July 1, 2026, reads: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW. This physician performs one (1) or more stem cell or regenerative medicine therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider before undergoing any stem cell or regenerative medicine therapy.”
Utah’s, at Utah Code 58-1-512, reads: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing a stem cell therapy.” Utah is the state you can check with your eyes, since the notice must sit on paper at least 8.5 by 11 inches, in no less than forty point type, prominently displayed at the entrance and in an area visible to patients.
The Florida Limit Matters Most Here
Florida authorizes non-FDA-approved stem cell therapy only when it falls within scope of practice and relates to orthopedics, wound care, or pain management. Erectile dysfunction is none of the three, so a Florida clinic offering it for erectile dysfunction is operating outside what the statute authorizes. Put that question to the clinic in writing.
The table below is a reference for the notice you should have received, by state. Match your row, then compare it against the advertisement you responded to, the consent form you signed, and in Utah, the wall.
| State | Notice you should have received | Where it must appear | Also check |
|---|---|---|---|
| Florida | Exact notice naming Florida law | Advertising | Use limited to orthopedics, wound care, or pain management, plus a post-thaw viability report before use |
| Georgia | Exact notice naming Georgia law | Advertising, in type no smaller than the largest used in the ad | Signed consent stating nature and character, non-approval, and anticipated results |
| Tennessee | Exact notice naming Tennessee law | Advertising | Consent signed before therapy, plus numeric viability thresholds unless autologous |
| Utah | Exact notice naming Utah law | Entrance, on paper at least 8.5 by 11 inches in no less than forty point type, and in advertising | Since May 6, 2026, suppliers ship only after written confirmation the provider will give the notice |
| California, Washington, Vermont | Disclosure that the therapy is not FDA approved, plus consent | Varies by state | California requires the Medical Board to report complaints and discipline |
| Texas, North Carolina, Mississippi, Wyoming | Written informed consent, no advertising notice | Consent form | Texas consent covers only eligible patients with severe chronic disease or terminal illness, under IRB oversight |
Print your row and hold it against what you were handed. A missing notice is a legal requirement you can verify without anyone’s help.
Erectile Dysfunction Stem Cell Clinic Red Flags in Marketing Language
The Federal Trade Commission regulates the advertising itself, separately from the FDA. Its Health Products Compliance Guidance, published December 20, 2022, requires competent and reliable scientific evidence for express and implied claims, clear and conspicuous disclosures, and testimonials that do not substitute for substantiation.
Patient quotes carry most of the persuasive weight in ED cell therapy marketing, and under that standard they are not evidence. Implied claims count too, so a page that never says a product works while surrounding it with recovery stories is still making one. Watch for a trial identifier printed without its status, registered placed where approved would go, accreditation described as though a regulator granted it, and refusal to name the product or manufacturer in writing. Our guide to unethical clinic warning signs shows how these look in practice.
Frequently Asked Questions
What specific questions should a patient ask an ED clinic before treatment?
Ask in writing for the exact product name, who manufactures it, where it is processed, its FDA regulatory status, and any trial identifier supporting the use offered. Request the consent form and any state notice before paying. Written answers can be checked against public records.
What credentials or registrations should a legitimate clinic be able to show?
Expect a current medical license in your state, a named supplier with FDA establishment registration or accreditation from a body such as AABB, the American Association of Tissue Banks, or the World Marrow Donor Association, and consent stating the product is not FDA approved.
What marketing language is a red flag specific to ED clinics?
Watch for registered used where approved belongs, testimonials standing in for evidence, and a trial number cited with no status. The FTC’s December 2022 guidance requires competent and reliable scientific evidence for express and implied claims alike. No stem cell product is approved for erectile dysfunction.
Where can patients check if a clinic has received an FDA warning letter?
The FDA maintains a public warning letters database, searchable by company name, subject, and issuing office. Search the clinic’s legal name, its trade name, the manufacturer, and the product, since a letter may name the supplier instead of the clinic. No result is not clearance.
Is any ADSC-based ED treatment currently FDA approved?
No. No adipose-derived cell product is FDA approved for erectile dysfunction. The FDA consumer alert states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is approved. Ryoncil, the only approved mesenchymal stromal cell therapy, is bone marrow derived.
What do the ClinicalTrials.gov statuses Unknown and Terminated actually mean?
Unknown describes a record whose last known status was recruiting, not yet recruiting, or active and not recruiting, that passed its completion date without verification in the past two years. Terminated means the study stopped early and will not start again. Withdrawn means it stopped before enrolling anyone.
Key Takeaways
Verification is a sequence of free lookups. Search the clinic, the manufacturer, and the product in the FDA warning letters database, and read any letter in full. Check the FDA list of approved cellular and gene therapy products, where absence is the expected result and the only approved mesenchymal stromal cell therapy is bone marrow derived. Read the consumer alert. Look up every cited trial and read the status field, because Unknown, Terminated, and Withdrawn records get quoted as if they were active.
Then check your state, since Florida, Georgia, Tennessee, and Utah each require a specific written notice, and Florida authorizes non-FDA-approved stem cell therapy only for orthopedics, wound care, and pain management. None of this establishes whether anything works. Adipose-derived cells remain investigational, the evidence is preliminary, outcomes cannot be predicted, and a licensed physician should guide any decision.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Patients weighing adipose tissue banking for potential future use can review current pricing or contact our team with questions about collection logistics.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including urology input is required before publication. Please consult your urologist before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: compliant marketing standards.
